Healthcare & Life Sciences
Type6
About
Type6 is developing a new class of bifunctional kinase inhibitors aimed at targeting a range of historically hard-to-target cancers using a rational engineering approach to create highly specific, high avidity molecules.
Explore Type6's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.